The conference is the world’s largest meeting dedicated to lung
cancer and other thoracic malignancies
ST. HELIER, Jersey--(BUSINESS WIRE)--
Novocure (NASDAQ: NVCR) announced today five data presentations at the
International Associations for the Study of Lung Cancer (IASLC) 18th
World Conference on Lung Cancer, October 15 to October 18 in Yokohama,
Japan.
“We look forward to having our research on Tumor Treating Fields
(TTFields) presented at the world’s largest meeting dedicated to lung
cancer and other thoracic malignancies,” said Dr. Eilon Kirson,
Novocure’s Chief Science Officer and Head of Research and Development.
“Lung cancer is the most common cause of cancer death worldwide.
TTFields shows promise in multiple solid tumor types, including some of
the most aggressive forms of cancer. We are committed to researching
TTFields as a treatment for multiple solid tumor types and sharing our
findings with the scientific community.”
The following posters will be presented at the IASLC World Conference on
Lung Cancer:
Advanced non-small cell lung cancer
(P3.01-088d) TTFields Combined with PD-1 Inhibitors or Docetaxel for 2nd
Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) (ID 7563): Phase 3
LUNAR Study. U. Weinberg, O. Farber, M. Giladi, Z. Bomzon, E. Kirson.
9:30 a.m. to 4 p.m. JST October 18. (Exhibit Hall, Hall B + C)
(P3.01-088e) TTFields Delivery to the Brain: An Overview of
Computational Studies and Implications When Treating Brain Metastases
(ID 8773). S. Levi, Z. Bomzon, A. Naveh, E. Kirson, U. Weinberg. 9:30
a.m. to 4 p.m. JST October 18. (Exhibit Hall, Hall B + C)
Clinical design, statistics and clinical trials
(P3.04-013b) TTFields and Radiosurgery for 1-10 Brain Metastases from
NSCLC: The Phase 3 METIS Study (ID 7562). M. Mehta, V. Gondi, M.
Ahluwalia, P. Brown. 9:30 a.m. to 4 p.m. JST October 18. (Exhibit Hall,
Hall B + C)
Immunology and immunotherapy
(P3.07-013c) Computational Simulations for Investigating Electric Field
Distributions When Delivering Tumor Treating Fields (TTFields) to the
Lungs (ID 8776). H. Hershkovich, O. Yesharim, N. Urman, A. Naveh, U.
Weinberg, E. Kirson, Z. Bomzon U. Weinberg. 9:30 a.m. to 4 p.m. JST
October 18. (Exhibit Hall, Hall B + C)
(P3.07-013d) Tumor Treating Fields Induce Immunogenic Cell Death and
Enhance Antitumor Effects of Anti-PD1 in NSCLC In-Vivo Models (ID 8952).
T. Voloshin, O. Yitzhaki, M. Giladi, N. Kaynan, A. Shteingauz, M.
Munster, R. Blat, Y. Porat, R. Schneiderman, E. Zeevi, S. Cahal, A.
Itzhaki, E. Kirson, U. Weinberg, Y. Palti. 9:30 a.m. to 4 p.m. JST
October 18. (Exhibit Hall, Hall B + C)
About Novocure
Novocure is an oncology company developing a profoundly different cancer
treatment utilizing a proprietary therapy called TTFields, the use of
electric fields tuned to specific frequencies to disrupt solid tumor
cancer cell division. Novocure’s commercialized product, Optune, is
approved for the treatment of adult patients with glioblastoma. Novocure
has ongoing or completed clinical trials investigating TTFields in brain
metastases, non-small cell lung cancer, pancreatic cancer, ovarian
cancer and mesothelioma.
Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New
Hampshire, Malvern, Pennsylvania and New York City. Additionally, the
company has offices in Germany, Switzerland, Japan and Israel. For
additional information about the company, please visit www.novocure.com
or follow us at www.twitter.com/novocure.
Forward-Looking Statements
In addition to historical facts or statements of current condition, this
press release may contain forward-looking statements. Forward-looking
statements provide Novocure’s current expectations or forecasts of
future events. These may include statements regarding anticipated
scientific progress on its research programs, development of potential
products, interpretation of clinical results, prospects for regulatory
approval, manufacturing development and capabilities, market prospects
for its products, and other statements regarding matters that are not
historical facts. You may identify some of these forward-looking
statements by the use of words in the statements such as “anticipate,”
“estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other
words and terms of similar meaning. Novocure’s performance and financial
results could differ materially from those reflected in these
forward-looking statements due to general financial, economic,
regulatory and political conditions as well as more specific risks and
uncertainties facing Novocure such as those set forth in its Annual
Report on Form 10-K filed on February 23, 2017, with the U.S. Securities
and Exchange Commission. Given these risks and uncertainties, any or all
of these forward-looking statements may prove to be incorrect.
Therefore, you should not rely on any such factors or forward-looking
statements. Furthermore, Novocure does not intend to update publicly any
forward-looking statement, except as required by law. Any
forward-looking statements herein speak only as of the date hereof. The
Private Securities Litigation Reform Act of 1995 permits this discussion.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171016005152/en/
Source: Novocure